These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34321404)

  • 1. Dysphagia From Long-Term Olanzapine Use: A Rare Adverse Effect.
    Idiculla PS; Siddiqui JH
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):600-601. PubMed ID: 34321404
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.
    Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Alexopoulos GS; Rudorfer MV; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Mulsant BH;
    JAMA; 2019 Aug; 322(7):622-631. PubMed ID: 31429896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting injectable olanzapine: post-injection syndrome.
    Prescrire Int; 2017 Feb; 26(179):46. PubMed ID: 30726633
    [No Abstract]   [Full Text] [Related]  

  • 4. Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.
    Garg S; Gupta D; Rakesh K; Tikka SK
    J Clin Psychopharmacol; 2019; 39(5):523-524. PubMed ID: 31433337
    [No Abstract]   [Full Text] [Related]  

  • 5. Involuntary Facial Twitching in a Patient with Schizophrenia on Treatment with Long Acting Injectable Olanzapine.
    Mustafa FA; Nayar A
    Psychopharmacol Bull; 2019 Jun; 49(2):63-64. PubMed ID: 31308585
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute Necrotizing Pancreatitis Associated With Orally Disintegrating Formulation of Olanzapine: Implications on Clinical Presentation and Management.
    Vaidyanathan S; Subramanian K; Bharadwaj B; Das S; Kola GST; Maroju NK
    J Clin Psychopharmacol; 2019; 39(5):519-521. PubMed ID: 31433336
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?
    Woon LS; Tee CK; Gan LLY; Deang KT; Chan LF
    J Psychiatr Pract; 2018 Mar; 24(2):121-124. PubMed ID: 29509183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysphagia in a Case of Atypical Neuroleptic Malignant Syndrome.
    Truong TD; Mason DP
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):349-351. PubMed ID: 33734166
    [No Abstract]   [Full Text] [Related]  

  • 9. Meningocele and ankyloblepharon following in utero exposure to olanzapine.
    Arora M; Praharaj SK
    Eur Psychiatry; 2006 Jul; 21(5):345-6. PubMed ID: 16545547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dosage of aripiprazole-induced dysphagia.
    Lin TW; Lee BS; Liao YC; Chiu NY; Hsu WY
    Int J Eat Disord; 2012 Mar; 45(2):305-6. PubMed ID: 21541978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
    Narendran R; Young CM; Valenti AM; Pristach CA; Pato MT; Grace JJ
    J Clin Psychiatry; 2001 Jul; 62(7):509-16. PubMed ID: 11488360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine-associated Edema Decreasing Serum Lithium Concentrations: A Case Report.
    Cusimano J; Martin C; VandenBerg A
    J Clin Psychopharmacol; 2020; 40(5):499-500. PubMed ID: 32858619
    [No Abstract]   [Full Text] [Related]  

  • 13. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.
    Weissman J; Flint A; Meyers B; Ghosh S; Mulsant B; Rothschild A; Whyte E;
    Psychiatry Res; 2012 May; 197(3):221-6. PubMed ID: 22464991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An unusual bullous eruption: olanzapine induced pseudoporphyria.
    Johnson OR; Stewart MF; Bakshi A; Weston P
    BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31678928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Olanzapine-Induced Fever.
    Yang CH; Chen YY
    Psychopharmacol Bull; 2017 Jan; 47(1):45-47. PubMed ID: 28138204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysphagia to Liquids Only Associated With Olanzapine: A Case Report.
    Kılıç NB; Korkmaz S
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):509-511. PubMed ID: 35776533
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzapine associated palpebral edema: An uncommon adverse effect of a commonly prescribed drug.
    Kuppili PP; Nebhinani N; Jain S; Singhai K
    Asian J Psychiatr; 2018 Aug; 36():60-61. PubMed ID: 29966888
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological considerations in antipsychotic drug selection for prevention of drug-induced dysphagia.
    Koshiishi T; Koinuma M; Takagi A; Nakamura H
    Pharmazie; 2020 Nov; 75(11):595-598. PubMed ID: 33239136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.
    Li H; Peng S; Li S; Liu S; Lv Y; Yang N; Yu L; Deng YH; Zhang Z; Fang M; Huo Y; Chen Y; Sun T; Li W
    Sci Rep; 2019 Feb; 9(1):1582. PubMed ID: 30733507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches.
    Shamshoum H; Medak KD; Wright DC
    Behav Brain Res; 2021 Feb; 400():113049. PubMed ID: 33290757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.